Jul

2011

Taris Biomedical, Inc.: Series B $18.3M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - Incontinence, X - Inflammation, X - Oncology, XX - MA

Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

May

2011

Scil Proteins, GmbH: Series B $33.8M

Posted in I - Series B, Q - 1Q11, R - INTERNATIONAL, X - Inflammation, X - Oncology

Scil Proteins (Germany) a clinical-stage biopharmaceutical company focused on inflammation, infectious disease and oncology, closed a $33.8M Series B financing. Participants include BioNet Holding.

Apr

2011

Aratana Therapeutics, Inc.: Series A $20M

Posted in I - Series A, Q - 1Q11, R - MID WEST, X - Cachexia, X - Inflammation, X - Oncology, X - Pain, X - Veterinary, XX - KS

Aratana Therapeutics (Kansas City, KS) a clinical-stage animal health company focused on pain, cancer, inflammation, cachexia and frailty, closed a $20M Series A financing. Participants include MPM Capital, Cultivian Ventures and Avalon Ventures.

Mar

2011

PanTheryx, Inc.: Series A $1M

Posted in I - Series A, Q - 1Q11, R - ROCKY MOUNTAIN, X - Inflammation, X - Pain, XX - CO

PanTheryx (Boulder, CO) a commercial-stage pharmaceutical company focused on the acquisition, development and commercialization of pain, inflammation, GERD, rhinitis and peripheral neuropathy products for the Indian healthcare market, closed a $1M Series A financing. Participants were not identified.

Jan

2011

Noxxon Pharma, AG: Series D $2.6M

Posted in I - Series D, Q - 4Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $2.6M Series D financing, bringing the total round to $42.6M. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, [...]

Jan

2011

Hutchinson MediPharma, Ltd.: Series B $12.5M

Posted in I - Series B, Q - 4Q10, R - INTERNATIONAL, X - Inflammation, X - Oncology

Hutchison MediPharma (China) a clinical-stage biopharmaceutical company focused on inflammatory bowel disease and oncology, closed a $12.5M Series B financing. Participants include SB China Venture Capital and Mitsui & Co.

Jan

2011

NovImmune, SA: Series B $20.8M

Posted in I - Series B, Q - 4Q10, R - INTERNATIONAL, X - Antibody, X - Immunology, X - Inflammation

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and immune related disorders, closed a $20.8M Series B financing. Participants include BZ Bank Aktiengesellschaft.

Oct

2010

Cara Therapeutics, Inc.: Series D $15M

Posted in I - Series D, Q - 3Q10, R - NORTH EAST, X - Inflammation, X - Pain, XX - CT

Cara Therapeutics (Shelton, CT) a clinical-stage small molecule company focused on pain and inflammation, closed a $15M Series D financing. Participants include Rho Ventures, Alta Partners, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Mitsubishi International and MVM Life Science Partners.

Oct

2010

Femta Pharmaceuticals, Inc.: Series A $2.2M

Posted in I - Series A, Q - 3Q10, R - WEST, X - Antibody, X - Autoimmune, X - Inflammation, XX - CA

Femta Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and autoimmune disease, closed a $2.2M Series A financing. Participants include Latterell Venture Partners.

Oct

2010

DecImmune Therapeutics, Inc.: Series A $1M

Posted in I - Series A, Q - 3Q10, R - NORTH EAST, X - Autoimmune, X - Inflammation, XX - MA

DecImmune Therapeutics (Boston, MA) a development-stage biopharmaceutica focused on inflammation and autoimmunity, closed a $1M Series A financing. Participants include Astellas Venture Management, Amgen Ventures and HealthCare Ventures.

Oct

2010

Tobria Therapeutics, Inc.: Series B $31M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Antiviral, X - HIV, X - Inflammation, XX - NJ

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Aug

2010

Calistoga Pharmaceuticals, Inc.: Series C $40M

Posted in I - Series C, Q - 3Q10, R - NORTH WEST, X - Inflammation, X - Oncology, X - PI3K, XX - WA

Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.

Aug

2010

Reata Pharmaceuticals, Inc.: Series D $78M

Posted in I - Series D, Q - 3Q10, R - SOUTH WEST, X - Inflammation, X - Renal, XX - TX

Reata Pharmaceuticals (Irving, TX) a clinical-stage small molecule company focused on inflammation modulation in chronic kidney disease, closed a $78M Series D financing. Participants include CPMG and Novo Ventures.

« Previous Entries Next Entries »

to top of page...